Back to Agenda
Professional Poster Session 2
Session Chair(s)
Representative Invited
DIA, United States
Professional and Student Posters provide an opportunity for methodology (“how to”), case study, and research to be presented to a diverse group of scientific professionals who are actively involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and healthcare-related products.
Learning Objective : Health inequities among underserved US populations are complex and related to unequal access to quality healthcare. Our objective was to identify healthcare professionals who, based on their expertise and areas of impact, can be considered potential partners in addressing healthcare disparities.
Speaker(s)
Health Equity and Inclusive Research Experts Profiling: Identifying Healthcare Professionals to Address Health Disparities
Daniel Alvarez, MD, MS
Genentech, A Member of the Roche Group, United States
Principal Medical Director, Health Equity and Inclusive Research (HEIR)
Dental Adverse Events with Transmucosal Buprenorphine Used to Treat Opioid Use Disorder and Pain: A Case Series
Samantha Cotter, PharmD
FDA, United States
Safety Evaluator
Characteristics of Opioid-Induced Hyperalgesia Occurring with Short and Long-Term Opioid Use
Sarah E Kang, PharmD, MS
FDA, United States
Safety Evaluator
Working with Patient Councils to Mitigate Drug-Related Risks
Raphael Elmadjian Pareschi, PharmD, MBA
Roche, Brazil
Patient Safety Lead/ Head of Pharmacovigilance Brazil
Using Historical RCT Controls Cohort to Contextualize Serious Adverse Events for ongoing RCTs
Chris Schneiderman, MPH
Abbvie, United States
Director - Epidemiology
Comparing Safety Between Generic and Brand Drugs of Statins Marketed in Japan: A Cohort Study
Hotaka Maruyama, MPharm
Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Division of PharmacoEpidemiology, Office of Pharmacovigilance ?
Comparison of US FDA and EMA Risk Minimization Strategies for Products with Eliminated REMS with ETASU and EU aRMMs
Tiffany Dominic, PharmD
Pfizer, United States
Risk Management Fellow
The Long-Term Safety of Tofacitinib as a Treatment for Moderate-to-Severe Ulcerative Colitis Based on Korean National Data
Sung Hoon Jung, DrMed, AHIP
The Catholic University of Korea, Korea, Republic of
Professor
A First-in-Human Study Evaluating Safety and Pharmacokinetics in Healthy Participants of the Heavy Metal Chelator HOPO 14-1
Laura Magda, MD, MSc
SRI International, United States
Director of Clinical Trials
Comprehensive Analysis of Pharmacovigilance Inspection Practices in the Pharmaceutical Industry in Saudi Arabia
Malak Almutairi, MSc, RPh
Saudi Food and Drug Authority, Saudi Arabia
Researcher
Drug Shortages in Saudi Arabia: A Cross-Sectional Study
Majdi Al Gharsan, PharmD
Ministry of Defence, Saudi Arabia
Director, Director of Medical Services
Effectiveness of the Additional Risk Minimization Measures for Luspatercept Among Healthcare Professionals in Europe
Samuel Ewusie, PharmD, MS, RPh
Bristol-Myers Squibb Company, United States
Associate Director, Safety Evidence and Science
Pioneering Use of a Decentralized Clinical Trial Model Leading to Faster Patient Recruitment in a Rare Cancer Study in Japan
Hiroya Taniguchi, MD
Aichi Cancer Center Hospital, Japan
Head Physician, Department of Clinical Oncology
Leveraging Real-World Data for a Culture of Learning in Health Systems: A Landscape Assessment
Matt D'Ambrosio
Duke-Margolis Institute For Health Policy, United States
Policy Analyst
The ACT ON Trial: Assisted Cascade Testing through Outreach and Navigation
Emily Epstein
Weill Cornell Medicine, United States
Clinical Behavioral Health Specialist
Implementing Clinical Trial to Real-World Data (RWD) Linkage
Mehdi Najafzadeh, PhD, MA, MS
Medidata AI, United States
Senior Director
EFFECT: An Epidemiological Framework For Equitable Representation of Racial and Ethnic Populations in Clinical Trials
Andrew R Marley
Parexel, Spain
Senior Epidemiologist
Pharmacist Training for Advanced Therapeutic use in a First in Human Study (FIH): Delivery of AAV9 CRISPR/Cas9 in Aviremic HIV Participants
Samantha Seepersad, MS
Excision Biotherapeutics, United States
AD
Identifying Novel Endpoints in Rare Disease Studies Using Real-World Evidence: A Regulatory Science Perspective
Christina Mack, PhD, MPH
IQVIA, United States
Chief Scientific Officer, Real-World Solutions
Decentralized Clinical Trials Platform Construction for Implementation in Ultra-Rare Cancer Clinical Trial in Japan
Hisahiro Ito, PhD, MS
National Cancer Center Japan, Japan
Head of Project Management Office
Important Tool in our Rare Disease Toolbox: Hybrid Retrospective-Prospective Natural History Studies as External Comparators
Gerd Rippin, DrSc
IQVIA, Germany
Senior Director, Biostatistics, Real-World Solutions
Innovation in Times of Uncertainty: The OPTIMAL Trials Experience Conducting a Large-Scale Clinical Trial after COVID-19
Bruna Sampaio
Hospital Israelita Albert Einstein, Brazil
Manager, Data management
Context and Comparative Effectiveness of Covid-19 Treatments: Predicting mortality, Rehospitalization, and Activities of Daily Living (ADLs) Across Covid-19 Variants and Treatments
Brittin Wagner, PhD, MA
PointClickCare, Canada
Senior Research Scientist
Optimizing Site and Country Selection for Clinical Trial Planning: a Mixed Integer Linear Programming Approach
Alexandru Socolov, MSc
Medidata Solutions, United States
Senior Data Scientist
Clinical Biomarkers: Implementing the Principles of Context-Of-Use for Biomarker Bioanalysis in Support of Drug Development
Sam Willcox
ACM Global Laboratories, United Kingdom
Section Manager - Large Molecule Bioanalysis
Development of Data and Artificial Intelligence (AI) Ethics Principles within a Pharmaceutical and Diagnostics Company
Timothe Menard, PharmD, MSc
F. Hoffmann-La Roche Ltd, Switzerland
Global Head, Quality Excellence Digital | Bioethics Coach (Data Ethics)
Using Structured Clinical Trial Information from the National Cancer Institute to Improve Cancer Clinical Trials Search
Rebecca Williams, PharmD, MPH
Essex, Part of Emmes Group, United States
Senior Clinical Trials Subject Matter Expert
The Use of Decentralized Research Technologies for the Continuity of Participant Follow Up during the COVID-19 Pandemic
Izabela Chaves Pedro, AHIP
Hospital Israelita Albert Einstein, Brazil
Clinical Research Associate
Professionals’ Perceptions on Differences Between RCT and EHR Data by Literature Review and on the Use of EHR Data by Survey
Cheryl Hergert, DrSc, MPH
University of Southern California, United States
From Dreams to Implementation: The Realities of Incorporating GenAI in Life Sciences and Healthcare
Matt Wampole, PhD, MA
Clarivate, United States
Director, Solution Consulting
Journey to the Center of Plain Language Summaries (PLS): A Retrospective analysis of Audience Engagement Measures
Ayush Sood, PharmD
Boehringer-Ingelheim Pharmaceuticals, Inc. , United States
Post-Doctoral Fellow, MASC, Clinical Development and Medical Affairs
Regulatory Updates: New Therapeutic Possibilities for the Brazilian Population
Renata Costa, MSc
Libbs Farmaceutica, Brazil
Specialist
Hereditary Transthyretin-Related Amyloidosis Ongoing Clinical Study: A Baseline Report of the First 3,167 Participants
Pierre Engel, PhD, MPharm
Centogene Gmbh, Germany
Senior Director Business Development
Optimization of Content Retrieval for Medical Information Scientific Responses by the Addition of Medical Conference Evidence
Joseph Laudano, PharmD
IQVIA, United States
Medical Director
Optimization of Content Retrieval for Medical Information Scientific Responses by the Addition of Medical Conference Evidence
Jennifer Riggins, PharmD
phactMI, United States
Technology and Partnership Strategist
Choosing the Right Design: A Guiding Framework for Using Direct-to-Patient, Hybrid and Conventional Site-Based Study Designs
Mui Van Zandt
IQVIA, United States
VP/Global Head, Data Strategy, Access and Enablement
Taiwan's Pediatric or Rare Severe Disease Priority Review Voucher Program: Enhancing Novel Drug Accessibility
Cheng Chi Chen, MSc
Center For Drug Evaluation, Taiwan
Clinical Reviewer
Update on a Biopharmaceutical Bioethics Consultation Service: 16-Year Descriptive Characteristics
Susan Watson, PhD
Eli Lilly and Company, United States
Associate Director, Bioethics
14 Day Continuous Purification Process Achieves Acceptable Bioburden and Product Quality
Celeste Lee Amadei
PAK Biosolutions, United States
Product Manager
Have an account?